Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.44
-0.28 (-3.63%)
At close: Apr 28, 2026, 4:00 PM EDT
7.30
-0.14 (-1.88%)
After-hours: Apr 28, 2026, 6:18 PM EDT

Fulcrum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2017
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2017
Revenue
--802.816.3419.16
Upgrade
Revenue Growth (YoY)
--2752.05%-55.77%-66.91%117.19%
Upgrade
Cost of Revenue
56.7856.163.3971.876.7869.7
Upgrade
Gross Profit
-56.78-56.116.61-69-70.44-50.54
Upgrade
Selling, General & Admin
29.7728.6736.4541.6741.6930.52
Upgrade
Operating Expenses
29.7728.6736.4541.6741.6930.52
Upgrade
Operating Income
-86.55-84.77-19.83-110.66-112.13-81.05
Upgrade
Interest & Investment Income
10.449.8912.1713.332.690.21
Upgrade
EBT Excluding Unusual Items
-76.12-74.88-7.66-97.34-109.44-80.85
Upgrade
Merger & Restructuring Charges
---2.06--0.43-
Upgrade
Pretax Income
-76.12-74.88-9.73-97.34-109.87-80.85
Upgrade
Net Income
-76.12-74.88-9.73-97.34-109.87-80.85
Upgrade
Net Income to Common
-76.12-74.88-9.73-97.34-109.87-80.85
Upgrade
Shares Outstanding (Basic)
676362614535
Upgrade
Shares Outstanding (Diluted)
676362614535
Upgrade
Shares Change (YoY)
7.54%2.21%1.10%36.27%27.23%39.47%
Upgrade
EPS (Basic)
-1.14-1.18-0.16-1.59-2.44-2.29
Upgrade
EPS (Diluted)
-1.14-1.18-0.16-1.59-2.44-2.29
Upgrade
Free Cash Flow
-63.88-60.38-2.5-91.47-99.01-80.19
Upgrade
Free Cash Flow Per Share
-0.96-0.95-0.04-1.49-2.20-2.27
Upgrade
Gross Margin
--20.77%---263.73%
Upgrade
Operating Margin
---24.79%-3945.24%-1768.12%-422.97%
Upgrade
Profit Margin
---12.16%-3470.05%-1732.43%-421.89%
Upgrade
Free Cash Flow Margin
---3.12%-3261.07%-1561.23%-418.47%
Upgrade
EBITDA
-85.18-83.38-18.24-108.49-109.72-78.54
Upgrade
EBITDA Margin
---22.80%---
Upgrade
D&A For EBITDA
1.381.391.592.172.412.52
Upgrade
EBIT
-86.55-84.77-19.83-110.66-112.13-81.05
Upgrade
EBIT Margin
---24.79%---
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.